Overview

AVENIO NGS Oncology Assay kits provide researchers a versatile solution for tumor tissue and ctDNA analysis with an integrated end-to-end workflow. With accurate and reliable analysis of ultra low ctDNA detection as well as formalin-fixed paraffin-embedded (FFPE) tissue samples, AVENIO NGS Oncology Assays offer laboratories ​​in-house tumor profiling, comprehensive genomic profiling (CGP), and surveillance & monitoring. Each kit includes reagents for DNA extraction, sample input QC (for tissue), library preparation, target enrichment, robust bioinformatics, secondary analysis and reporting (variant calls).

 

Key advantages of AVENIO NGS Oncology Assays

  • Flexibility to switch between tissue and plasma to support a variety of research applications, from targeted and expanded profiling to surveillance & monitoring*
  • Matched tissue and ctDNA panels (same genes, gene regions and hybrid-capture workflow) for true concordance*
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow with exceptional sensitivity and specificity1
  • A streamlined, end-to-end workflow from extraction to analysis and reporting in 5 days
  • An integrated solution that includes reagents, intuitive analysis and reporting to facilitate in-house adoption of high performance NGS oncology research
  • Designed to match the 324 gene FoundationOne® CDx panel content, CGP assay also enables detection of genomic signatures -- tumor mutational burden (TMB), microsatellite instability (MSI) and loss of heterozygosity (LOH)

 

*CGP is available for tissue only

Example research use cases

AVENIO kits contain gene panels with biomarkers relevant to clinical cancer research over the course of disease evolution.

 

  1. Data on file.
  1. National Comprehensive Cancer Network. October 15, 2016.